Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in HER2-negative Metastatic Breast Cancer
NCT00425854Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2006
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of afatinib in breast cancer, sponsored by Boehringer Ingelheim. Primary endpoints: Objective Response and Clinical Benefit. Started Nov 2006; status: completed.
02
Drugs
afatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00425854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425854.